PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Lynderup, E.M.* ; Vendelbo, M.H.* ; Kirk, F.T.* ; Vase, K.H.* ; Alstrup, A.K.O.* ; Rieder, T.* ; DiSpirito, A.A.* ; Semrau, J.D.* ; Laursen, T.L.* ; Ott, P.* ; Zischka, H. ; Sandahl, T.D.*

Methanobactin rapidly facilitates biliary copper excretion in a Wilson disease rat model visualised by 64Cu PET/MRI.

Br. J. Pharmacol., DOI: 10.1111/bph.70099 (2025)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND AND PURPOSE: Methanobactins are peptides with high copper affinity and potential to treat Wilson disease. We examined how two methanobactins (ARBM101 and MB-OB3b) affected copper handling in the LPP Atp7b-/- Wilson disease rat model, compared to penicillamine or saline, by 64Cu positron emission tomography/magnetic resonance imaging. Heterozygotes served as controls. EXPERIMENTAL APPROACH: 64Cu was administered i.v. to 19 LPP and four control rats. A baseline scan was performed 1 h later. LPP rats received one dose of saline, penicillamine, MB-OB3b or ARBM101 i.p. (t = 100 min), followed by a 90-min scan and a final scan at t = 24 h. Controls followed identical procedures without intervention. 64Cu levels were evaluated as % injected dose (%ID) in the liver, kidney and 'abdominal-pelvic region' (intestines and other non-hepatic, non-renal organs). KEY RESULTS: At baseline, hepatic %ID was ≈50% higher in LPP rats than in controls. Intraintestinal 64Cu activity, indicating biliary excretion, was present in controls and absent in LPP rats. After methanobactin injection (but not saline or penicillamine), 64Cu appeared in the small intestines of LPP rats within 10-15 min. Hepatic %ID increased over 24 h in saline-, penicillamine- and MB-OB3b-injected rats but decreased in control rats. ARBM101 almost normalised hepatic 64Cu at 24 h. CONCLUSIONS AND IMPLICATIONS: A single i.p. methanobactin dose restored biliary copper excretion in LPP rats. The effect was more pronounced with ARBM101 than with MB-OB3b. Non-ATP7B transporters must be involved because ATP7B is absent in LPP rats. Methanobactin may have therapeutic potential in Wilson disease.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Chelation Therapy ; Positron‐emission Tomography ; Copper Metabolism ; Copper‐binding Protein; Positron-emission-tomography; Therapy; Binding; Strain; Metabolism; Diagnosis; Efficacy; Gene
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 0007-1188
e-ISSN 1476-5381
Zeitschrift British Journal of Pharmacology
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Molecular Toxicology and Pharmacology (TOX)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-505200-003
Förderungen The Memorial Foundation of Manufacturer Vilhelm Pedersen and Wife
DOI 10.1111/bph.70099
WOS ID 001561292200001
Scopus ID 105014732202
PubMed ID 40890927
Erfassungsdatum 2025-11-13
[➜Korrektur melden]